Head to Head Review: Nuwellis (NASDAQ:NUWE) & Delcath Systems (NASDAQ:DCTH)

Nuwellis (NASDAQ:NUWE) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Nuwellis and Delcath Systems”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27 million	0.23	-$17.52 million	($64.02)	-0.01
Delcath Systems	$90.44 million	4.05	$2.70 million	$0.01	1,060.00

Delcath Systems has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Nuwellis and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Delcath Systems	0.62%	0.51%	0.46%

Risk & Volatility

Nuwellis has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Nuwellis and Delcath Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1	0	0	0	1.00
Delcath Systems	2	0	5	0	2.43

Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 112.26%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts plainly believe Delcath Systems is more favorable than Nuwellis.

Summary

Delcath Systems beats Nuwellis on 14 of the 14 factors compared between the two stocks.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.